Literature DB >> 33839706

A comparative analysis of COVID-19 outbreak on age groups and both the sexes of population from India and other countries.

Shweta Jakhmola1, Budhadev Baral1, Hem Chandra Jha2.   

Abstract

INTRODUCTION: The study of epidemiological outcomes of COVID-19 in the affected countries needs to be conducted to implement an effective strategy.
METHODOLOGY: Our study included age and sex-based analysis of epidemiological data of infected and deceased patients from various countries. The patient data was graphically depicted with the slope's calculation to describe a gradual or steep spread of the disease along with subsequent rise or fall in the death reports.
RESULTS: Population groups of 20-49 years of age and 50 years-above were highly vulnerable to infection. Interestingly, 20-49 years of age group was most affected in India. However, higher population of the deceased were reported in the 50 years-above in all countries. India and South Korea demonstrated a gradual appearance of COVID-19 positive cases than other countries illustrated by reduced slope %. Further the highest percentage of infected people and deaths were reported from the densely populated states of India. We observed a sex independent prevalence of COVID-19. The BCG and JE vaccine are unique in the vaccination regime of India and South Korea.
CONCLUSIONS: Reduced ACE-2 expression in the children's nasal epithelium may be responsible for reduced SARS-CoV-2 susceptibility. Countries showed varying patterns in COVID-19 spread and associated mortality. It may be influenced by factors, such as screening strategy, countries demography, implementation of lockdown, etc. Due to limited evidence, it would be difficult to point to the influence of the virus on either sexes. Although vaccines may stimulate non-specific immunity, experimental proofs are needed to demonstrate the potential of any vaccine against SARS-CoV-2. Copyright (c) 2021 Shweta Jakhmola, Budhadev Baral, Hem Chandra Jha.

Entities:  

Keywords:  COVID-19; India; SARS-CoV-2; age group; epidemiology; immunization

Year:  2021        PMID: 33839706     DOI: 10.3855/jidc.13698

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  6 in total

1.  Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in children and adolescents in Delhi, India, from January to October 2021: a repeated cross-sectional analysis.

Authors:  Pragya Sharma; Saurav Basu; Suruchi Mishra; Mongjam Meghachandra Singh
Journal:  Osong Public Health Res Perspect       Date:  2022-06-10

2.  Excess all-cause mortality and COVID-19 reported fatality in Iran (April 2013-September 2021): age and sex disaggregated time series analysis.

Authors:  Seyed Amir Ahmad Safavi-Naini; Yeganeh Farsi; Walid Q Alali; Ali Solhpour; Mohamad Amin Pourhoseingholi
Journal:  BMC Res Notes       Date:  2022-04-05

3.  Mutational analysis of structural proteins of SARS-CoV-2.

Authors:  Shweta Jakhmola; Omkar Indari; Dharmendra Kashyap; Nidhi Varshney; Ayan Das; Elangovan Manivannan; Hem Chandra Jha
Journal:  Heliyon       Date:  2021-03-20

Review 4.  COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity.

Authors:  Mi-Hyun Lee; Bum-Joon Kim
Journal:  J Microbiol       Date:  2022-02-14       Impact factor: 2.902

5.  Obesity as an Important Marker of the COVID-19 Pandemic.

Authors:  Irfan A Mir; Renu Soni; Shrey K Srivastav; Inimerla Bhavya; Waseem Q Dar; Malik D Farooq; Vrinda Chawla; Mir Nadeem
Journal:  Cureus       Date:  2022-01-19

Review 6.  SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era.

Authors:  Haifa Khemiri; Kaouther Ayouni; Henda Triki; Sondes Haddad-Boubaker
Journal:  Virol J       Date:  2022-09-08       Impact factor: 5.913

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.